RomSi: Mobile Health Intervention to Enhance Suicide Prevention by Reducing Stigma and Increasing Literacy
Launched by UNIVERSITY OF VALENCIA · Dec 27, 2024
Trial Information
Current as of November 14, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called RomSi, is focused on reducing the stigma around suicide and increasing awareness about it in order to prevent suicidal thoughts and behaviors. In Spain, suicide is a major public health issue, and many people who need help don’t seek it because they feel embarrassed or ashamed. The trial will create a mobile health program that provides information and support to the general public, especially targeting two specific groups: individuals with low suicidal thoughts and the loved ones of those who have died by suicide. Participants will be asked to use this mobile program and share their experiences, helping researchers understand how effective it is in encouraging people to seek help and learn more about suicide.
To participate in this study, individuals must be at least 18 years old, have a cell phone with internet access, and be able to read and understand Spanish. However, people who show signs of high suicidal thoughts or other serious mental health issues will not be eligible to join. Participants can expect to use the mobile health program and provide feedback on their experience over the course of the trial. The researchers aim to find out if the program can successfully increase knowledge about suicide, reduce feelings of stigma, and encourage people to reach out for help when they need it.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Be 18 years old or older.
- • Have a cell phone with internet access during the intervention and follow-up periods.
- • Be able to speak, understand, and read in Spanish.
- Exclusion Criteria:
- • Presence of high suicidal ideation (measured during screening, with a score above 20 on the total SIDAS scale or between 7 and 10 on the item assessing suicide attempts).
- • Presence of high social desirability bias (measured during screening, with a score of 14 or higher on the MC-SDS scale).
- • Altered mental status that impedes the ability to provide informed consent or assent (e.g., acute psychosis, intoxication, or mania).
About University Of Valencia
The University of Valencia, a prestigious institution located in Spain, is dedicated to advancing scientific knowledge and improving public health through innovative research. With a strong emphasis on interdisciplinary collaboration, the university engages in a wide array of clinical trials aimed at addressing pressing medical challenges. Its commitment to ethical standards and regulatory compliance ensures the integrity of its research initiatives, while its experienced team of researchers and clinicians work diligently to translate scientific discoveries into practical applications that benefit patients and communities. The University of Valencia is at the forefront of medical research, fostering a culture of excellence and innovation in the pursuit of better healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Valencia, Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported